

Hyperthyreose: Diagnostik und Therapie

Hyperthyroïdie: diagnostic et traitement

Literatur / Références

1. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 2012; 379(9821):1155–1166.
2. Wilson S, Parle JV, Roberts LM et al. Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J Clin Endocrinol Metab 2006; 91(12):4809–4816.
3. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev 2012; 12(2):107–113.
4. Mariotti S, Caturegli P, Piccolo P, Barbesino G, Pinchera A. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 1990; 71(3):661–669.
5. Villaloid MC, Yokoyama N, Izumi M et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995; 80(9):2830–2833.
6. Braga-Basaria M, Basaria S. Marine-Lenhart syndrome. Thyroid 2003; 13(10):991.
7. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 2003; 88(5):2100–2105.
8. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22(2):240–254.
9. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010; 6(8):431–443.
10. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998; 338(11):712–718.
11. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005; 294(1):71–80.
12. Haentjens P, Van MA, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008; 159(3):329–341.
13. Ochs N, Auer R, Bauer DC et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148(11):832–845.
14. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379(9821):1142–1154.
15. Collet TH, Gussekloo J, Bauer DC et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172(10):799–809.
16. Bauer DC, Ettlinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134(7):561–568.
17. Lee JS, Buzkova P, Fink HA et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 2010; 170(21):1876–1883.
18. Glinoer D, de NP, Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001; 144(5):475–483.
19. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998; 8(2):119–124.
20. Vitti P, Rago T, Chiovato L et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7(3):369–375.
21. De GL, Abalovich M, Alexander EK et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97(8):2543–2565.
22. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001; 86(6):2354–2359.